Evidence map›Paper›PMID 36012766›Full record

ArticleInternational journal of molecular sciences2022

Decoding Functional High-Density Lipoprotein Particle Surfaceome Interactions.

Kathrin Frey, Sandra Goetze, Lucia Rohrer, Arnold von Eckardstein, Bernd Wollscheid

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Apolipoproteins in Health and Disease.International journal of molecular sciences · 2024
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Kathrin FreyInstitute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, 8093 Zurich, Switzerland.ORCID 0000-0003-0648-0589
Sandra GoetzeInstitute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, 8093 Zurich, Switzerland.ORCID 0000-0001-6880-8020
Lucia RohrerInstitute for Clinical Chemistry, University Hospital Zurich, 8091 Zurich, Switzerland.
Arnold von EckardsteinInstitute for Clinical Chemistry, University Hospital Zurich, 8091 Zurich, Switzerland.ORCID 0000-0002-1666-2266
Bernd WollscheidInstitute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, 8093 Zurich, Switzerland.
SIB Swiss Institute of Bioinformatics · CHUniversity Hospital of Zurich · CHETH Zurich · CH

Funding

ETH Personalized Health and Related Technologies strategic focus area 2022-601ETH Zurich 30 17-1Swiss National Science Foundation 310030-185109Swiss National Science Foundation 31003A_160259SystemsX.ch 2014/267
6 · The paper itself

Abstract

High-density lipoprotein (HDL) is a mixture of complex particles mediating reverse cholesterol transport (RCT) and several cytoprotective activities. Despite its relevance for human health, many aspects of HDL-mediated lipid trafficking and cellular signaling remain elusive at the molecular level. During HDL's journey throughout the body, its functions are mediated through interactions with cell surface receptors on different cell types. To characterize and better understand the functional interplay between HDL particles and tissue, we analyzed the surfaceome-residing receptor neighborhoods with which HDL potentially interacts. We applied a combination of chemoproteomic technologies including automated cell surface capturing (auto-CSC) and HATRIC-based ligand-receptor capturing (HATRIC-LRC) on four different cellular model systems mimicking tissues relevant for RCT. The surfaceome analysis of EA.hy926, HEPG2, foam cells, and human aortic endothelial cells (HAECs) revealed the main currently known HDL receptor scavenger receptor B1 (SCRB1), as well as 155 shared cell surface receptors representing potential HDL interaction candidates. Since vascular endothelial growth factor A (VEGF-A) was recently found as a regulatory factor of transendothelial transport of HDL, we next analyzed the VEGF-modulated surfaceome of HAEC using the auto-CSC technology. VEGF-A treatment led to the remodeling of the surfaceome of HAEC cells, including the previously reported higher surfaceome abundance of SCRB1. In total, 165 additional receptors were found on HAEC upon VEGF-A treatment representing SCRB1 co-regulated receptors potentially involved in HDL function. Using the HATRIC-LRC technology on human endothelial cells, we specifically aimed for the identification of other bona fide (co-)receptors of HDL beyond SCRB1. HATRIC-LRC enabled, next to SCRB1, the identification of the receptor tyrosine-protein kinase Mer (MERTK). Through RNA interference, we revealed its contribution to endothelial HDL binding and uptake. Furthermore, subsequent proximity ligation assays (PLAs) demonstrated the spatial vicinity of MERTK and SCRB1 on the endothelial cell surface. The data shown provide direct evidence for a complex and dynamic HDL receptome and that receptor nanoscale organization may influence binding and uptake of HDL.

Indexed as

Lipoproteins, HDLVascular Endothelial Growth Factor Ac-Mer Tyrosine KinaseHumansLigandsReceptors, Cell SurfaceReceptors, Scavengerc-Mer Tyrosine KinaseLigandsLipoproteins, HDLReceptors, Cell SurfaceReceptors, ScavengerVascular Endothelial Growth Factor AchemoproteomicsHDLligand–receptor interactionsmolecular healthreceptomesignalingspatial proteotypingsurfaceome

Identifiers

PMID36012766
PMCPMC9409371
OpenAlexW4292687756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.